BARDA Expands Partnership With Evidation to Validate and Improve Machine Learning Models for Early Detection of Influenza-like Illness Using Wearables

The Detect & Protect Studies will enroll 25,000 people to advance the development of influenza-like illness (ILI) detection models and test early behavioral interventions to improve outcomes

SAN MATEO, Calif.--(BUSINESS WIRE)-- Evidation, the company creating new ways to measure and improve health in everyday life, today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services (HHS), to fund the 2023 Influenza-like Illness (ILI) Detect & Protect Studies.

The Detect & Protect Studies will support the development of machine learning models to detect respiratory viral infections with data collected from consumer-grade wearable devices. This research will take place during the 2023-24 cold and flu season and bring together new devices and data types, serial PCR testing, and Evidation’s health measurement and engagement platform to create next-generation models for earlier and pre-symptomatic detection of COVID-19, influenza A and B, and respiratory syncytial virus (RSV).

This contract will also fund research to expand and better understand the potential impact of Evidation’s FluSmart program to encourage protective health behaviors. FluSmart pairs machine learning predictions with behavioral nudges, education, and personalized insights to help people better understand their risk of flu-like illness and take early action to help prevent transmission and severe disease.

This is the third BARDA award issued to Evidation to advance understanding and detection tools for respiratory infections. The first award funded the Home Testing of Respiratory Illness Study, a prospective flu monitoring study and benchmark dataset that used consumer wearables, self-reported symptoms, and PCR testing to understand and characterize respiratory virus onset. In 2020, BARDA funded follow-on research to investigate if and how machine learning models and novel data from wearables could be used to detect symptoms of COVID-19 infection.

“Since our first study with BARDA in December of 2019, with the participation and consent of hundreds of thousands of Americans nationwide, we’ve learned how high-resolution data from consumer grade wearables–heart rate, sleep, physical activity and other more specific signals–can help identify when someone may be experiencing symptoms of flu-like illness,” said Christine Lemke, co-founder and CEO of Evidation. “We are excited to expand, validate, and improve our models, and find new ways to prompt people to take appropriate action when it matters most.”

This project is being funded in whole or in part with federal funds from the Department of Health and Human Services; Administration of Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50123C00069.

About Evidation

Evidation creates new ways to measure and improve health in everyday life—making proactive, personalized, and truly human-centered healthcare possible. By connecting directly with millions of individuals, Evidation harnesses real-world data to deeply understand health experiences, rapidly and at scale. Evidation’s privacy-centric digital health measurement and engagement platform uses data science and machine learning to translate these everyday insights into high-impact health guidance, treatments, and tools. Founded in 2012, Evidation is headquartered in California with employees working around the globe.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231017686697/en/

Contacts

Amy Puliafito
press@evidation.com

Source: Evidation

Powered by Business Wire

View this news release online at:
http://www.businesswire.com/news/home/20231017686697/en

Back to news